Effects of SNF472, a Novel Inhibitor of Hydroxyapatite Crystallization in Patients Receiving Hemodialysis - Subgroup Analyses of the CALIPSO Trial - Raggi, Paolo (Division of Cardiology and Department of Medicine, University of Alberta, Edmonton, Alberta, Canada) ; Bellasi, Antonio (Research, Innovation and Brand Reputation Unit, ASST Papa Giovanni XXIII, Bergamo, Italy) ; Sinha, Smeeta (Department of Renal Medicine, Salford Royal NHS Foundation Trust, Salford, United Kingdom) ; Bover, Jordi (Institut d'Investigació Biomèdica Sant Pau) ; Rodriguez, Mariano (Hospital Universitario Reina Sofía (Còrdova, Espanya)) ; Ketteler, Markus (Department of General Internal Medicine and Nephrology, Robert-Bosch-Krankenhaus, Stuttgart, Germany) ; Bushinsky, David A. (Department of Medicine, University of Rochester School of Medicine, Rochester, New York, USA) ; Garg, Rekha (PharmaDRS, LLC, San Diego, California, USA) ; Perelló, Joan (University of the Balearic Islands, Palma, Spain) ; Gold, Alex (Department of Medicine, Stanford University, Palo Alto, California, USA) ; Chertow, Glenn M. (Department of Medicine, Stanford University, Palo Alto, California, USA) ; Universitat Autònoma de Barcelona